General description
A cell-permeable 8-hydroxyquinoline compound that is reported to inhibit nuclear E2F complexes DNA binding activity (IC50 = 30 µM) and downregulate E2F expression in the melanoma cell line A375, resulting in eventual apoptosis induction without upregulating p53 expression as commonly seen with traditional chemotherapeutic agents, such as Cisplatin (Cat. No. 232120), doxorubicin (Cat. No. 324380), and VP-16 (Cat. No. 341205).
A cell-permeable 8-hydroxyquinoline compound that is reported to inhibit nuclear E2F complexes DNA binding activity (IC50 = 30 µM) and downregulate E2F expression in the melanoma cell line A375, resulting in eventual apoptosis induction without upregulating p53 expression as commonly seen with traditional chemotherapeutic agents, such as Cisplatin (Cat. No. 232120), doxorubicin (Cat. No. 324380), and VP-16 (Cat. No. 341205).
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Ma, Y., et al. 2008. Cancer Res.68, 6292.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51111769
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- 324461-10MG
- CAS:
- 353519-63-8
